Lena Ortiz

A pen name, stated plainly

Lena Ortiz is not a legal name, and there is no photo on this page because a face would suggest a person you could look up. Lena Ortiz is not presented as a clinician, and the site makes no claim that a physician, pharmacist, nurse or dietitian wrote or medically reviewed what is published here. What the name stands for is a consistent set of rules, written down below and in our editorial policy, that you can check every page against.

What she covers

GLP-1 medications taken at low and standard doses: semaglutide and tirzepatide, the brand-name pens and the compounded versions, oral and sublingual formats, and the newer drugs still in trials. The questions are the ones readers actually bring — whether a small dose does anything, what it is likely to do to you, how people measure and schedule it, and what it costs from the telehealth companies that sell it. Microdosing is off-label, and there are no dedicated randomized trials of it; every page says so.

How provider reviews are researched

Each provider review is written from the company's own published pages: its pricing page, its plan terms, its FAQ and the way it describes its program. The price printed is the one on the company's public website, not a promotional rate from a referral link, and the byline under the headline shows the month that price was last read. Where a company publishes no price, or gates it behind an intake form, the review says so instead of estimating. No company previews, approves or edits its review.

Some companies pay us a commission when a reader signs up through our link, and those partners are listed first on our rankings. Their reviews carry the same trade-offs a non-partner's would. The full arrangement is on our funding disclosure page.

How evidence articles are sourced

In the research library, every medical or efficacy claim is cited to primary research — peer-reviewed trials and studies, linked to PubMed where one exists — or to the FDA prescribing information for the drug. The strength of the human evidence is graded claim by claim, null results are reported alongside positive ones, and where a claim rests on extrapolation from full-dose trials the article says that rather than implying a low-dose trial exists. Each article's byline shows the month it was written.

Corrections

If a price, a fact or a citation is wrong, email care@lowdoseglp1.com with the page and what you found. We check it against the original source, correct the page, and note the change. More on who runs this site.